ArticleNeuroradiology2025
Percutaneous management of pyogenic spondylodiscitis using absorbable antibiotic carrier (STIMULAN®): preliminary results from a single-center study.
Article in Neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluates the feasibility of using a fully resorbable antibiotic carrier (STIMULAN®, Rapid Cure, Biocomposites Ltd, UK) for the targeted treatment of spondylodiscitis (SD) through percutaneous injection directly into the infection site. MATERIAL AND
methodsBetween 2022 and 2024, 13 patients diagnosed with SD underwent percutaneous osteo-discal biopsy followed by intradiscal and intravertebral injection of tailored antibiotic-loaded calcium sulfate paste. Clinical assessments (VAS), laboratory markers (CRP and leukocyte counts), and MRI imaging were used to monitor outcomes up to 12 months.
resultsThe procedure achieved 100% technical success with no major complications. All patients showed significant symptom relief, with VAS scores decreasing from 8.2 at baseline to 3.5 at 12 months. Inflammatory markers improved consistently, particularly CRP, which dropped from 7.35 to 0.23 (p ≈ 0.00005).
conclusionsThese findings suggest that STIMULAN® enables safe, effective local antibiotic delivery in SD, with meaningful clinical and biomarker improvements. Nonetheless, larger multicenter studies are needed to validate these preliminary results and assess long-term efficacy.
Indexed as
Identifiers
40515821What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.